MLH1 and cancer: Most MSI tumours arise sporadically [6] (74%, 97%, and 63% of endometrial, gastric, and CRC MSI cancer cases, respectively), often associated with an hypermethylation of the MLH1 promoter (all localizations) or a BRAF V600E mutation (in CRC specifically) [7].